Mirna Therapeutics is a biopharmaceutical company working to develop a broad pipeline of leading microRNA-based cancer therapies. They are the first group to show that microRNA’s, small non-coding RNA molecules that function in RNA silencing and post-transcriptional regulation of gene expression, can be utilized as a replacement therapy for cancer. In the midst of the exciting research and discoveries underway at Mirna Therapeutics, Clay Siegall was appointed to Board of Directors in early 2013. Dr. Siegall announced, “MicroRNA-based therapeutics are an exciting area of cancer research, and Mirna is well-positioned with a strong pipeline of product candidates”. The company’s primary position as pioneers of the field of microRNA’s as therapeutics is what attracted Dr. Clay Siegall to join.
Having a strong research background himself, Dr. Siegall is the co-founder of Seattle Genetics, a biotechnology company focused on developing antibody-based therapeutics for cancer treatment. He is currently the company’s President, Chief Executive Officer, and Chairman of the Board. Seattle Genetics has had success in the development of ADCETRIS, it’s first commercial product, a drug indicated for the treatment of patients with progressive multifocal leukoencephalopathy. Since 1998, Seattle Genetics has entered into a slew of strategic licenses for it’s antibody therapeutic technologies.
Prior to co-founding Seattle Genetics, Dr. Siegall obtained a Bachelors of Science in Zoology from the University of Maryland and a PhD in Genetics from The George Washington University. He has received many awards and honors, including the 2012 Entrepreneur of the Year from Ernst & Young of the Pacific Northwest, and the 2013 Alumnus of the Year for Computer, Math, and Natural Sciences from the University of Maryland.